Pias1-Mediated Gsk3Β Sumoylation Exacerbates Tauopathy And Cognitive Deficits In Alzheimer’S Disease Models
Alzheimer’s disease, a common age-related neurodegenerative disorder, is characterized by the harmful buildup of a protein called Tau, leading to memory and cognitive problems. While a process known as SUMOylation, where small proteins (SUMO) attach to other proteins, is known to influence this Tau pathology, the exact mechanisms have been unclear.
Recent research has identified a key player in this process: a protein called PIAS1. Scientists found that PIAS1 acts as a critical driver of Tau pathology. It directly interacts with and modifies another protein, glycogen synthase kinase 3 beta (GSK3β), by attaching SUMO proteins to it. This specific modification makes GSK3β more active, which then leads to increased phosphorylation and aggregation of the Tau protein, ultimately worsening brain cell dysfunction and cognitive deficits.
Interestingly, levels of PIAS1 are elevated in the brains of individuals with Alzheimer’s disease and in animal models of the condition. Building on this discovery, researchers developed a special molecule, a cell-permeable blocking peptide, designed to interrupt the interaction between PIAS1 and GSK3β. When administered, this peptide successfully reduced the overactivity of GSK3β and lessened the Tau pathology and neurodegeneration in both laboratory and animal models.
These findings shed light on a previously unknown signaling pathway involving PIAS1 and GSK3β in the development of Tau-related diseases. This new understanding offers a promising target for developing innovative therapeutic strategies to combat Alzheimer’s disease.
Source: link to paper